
|Videos|April 19, 2022
Efficacy Data from Clinical Trials of Ruxolitinib in Primary MF
Author(s)Srdan Verstovsek, MD, PhD
A comprehensive review of key efficacy data from clinical trials on ruxolitinib, including COMFORT-I and COMFORT-II.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5

























